Evidence map›Paper›PMID 26726942›Full record

ArticleBone marrow transplantation2016

Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.

S Afifi, N G Adel, S Devlin, E Duck, J Vanak, H Landau, D J Chung, N Lendvai, A Lesokhin, N Korde and 4 more

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Review
  12. Observational
  13. Review
  14. Review
  15. Article
  16. Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

S AfifiPharmacy Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
N G AdelPharmacy Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S DevlinMemorial Sloan Kettering Cancer Center, New York, NY, USA.
E DuckMemorial Sloan Kettering Cancer Center, New York, NY, USA.
J VanakMemorial Sloan Kettering Cancer Center, New York, NY, USA.
H LandauMemorial Sloan Kettering Cancer Center, New York, NY, USA.
D J ChungMemorial Sloan Kettering Cancer Center, New York, NY, USA.
N LendvaiMemorial Sloan Kettering Cancer Center, New York, NY, USA.
A LesokhinMemorial Sloan Kettering Cancer Center, New York, NY, USA.
N KordeMemorial Sloan Kettering Cancer Center, New York, NY, USA.
L ReichMemorial Sloan Kettering Cancer Center, New York, NY, USA.
O LandgrenMemorial Sloan Kettering Cancer Center, New York, NY, USA.
S GiraltMemorial Sloan Kettering Cancer Center, New York, NY, USA.
H HassounMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Cyclophosphamide plus G-CSF (C+G-CSF) is one of the most widely used stem cell (SC) mobilization regimens for patients with multiple myeloma (MM). Plerixafor plus G-CSF (P+G-CSF) has demonstrated superior SC mobilization efficacy when compared with G-CSF alone and has been shown to rescue patients who fail mobilization with G-CSF or C+G-CSF. Despite the proven efficacy of P+G-CSF in upfront SC mobilization, its use has been limited, mostly due to concerns of high price of the drug. However, a comprehensive comparison of the efficacy and cost effectiveness of SC mobilization using C+G-CSF versus P+G-CSF is not available. In this study, we compared 111 patients receiving C+G-CSF to 112 patients receiving P+G-CSF. The use of P+G-CSF was associated with a higher success rate of SC collection defined as ⩾5 × 10(6) CD34+ cells/kg (94 versus 83%, P=0.013) and less toxicities. Thirteen patients in the C+G-CSF arm were hospitalized owing to complications while none in the P+G-CSF group. C+G-CSF was associated with higher financial burden as assessed using institutional-specific costs and charges (P<0.001) as well as using Medicare reimbursement rates (P=0.27). Higher rate of hospitalization, increased need for salvage mobilization, and increased G-CSF use account for these differences.

Indexed as

CyclophosphamideGranulocyte Colony-Stimulating FactorHeterocyclic CompoundsMultiple MyelomaAutograftsBenzylaminesCosts and Cost AnalysisCyclamsFemaleHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMaleBenzylaminesCyclamsCyclophosphamideGranulocyte Colony-Stimulating FactorHeterocyclic Compoundsplerixafor

Identifiers

PMID26726942
PMCPMC7337097
OpenAlexW2226813273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.